Dashboard
1
Poor Management Efficiency with a low ROE of 1.05%
- The company has been able to generate a Return on Equity (avg) of 1.05% signifying low profitability per unit of shareholders funds
2
Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.46 times
3
Poor long term growth as Net Sales has grown by an annual rate of 9.87% and Operating profit at 52.69% over the last 5 years
4
With a growth in Net Profit of 30.4%, the company declared Outstanding results in Mar 25
Stock DNA
Pharmaceuticals & Biotechnology
PLN 343 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.05
-0.45%
0.58
Revenue and Profits:
Net Sales:
66 Million
(Quarterly Results - Mar 2025)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.56%
0%
-4.56%
6 Months
-2.93%
0%
-2.93%
1 Year
31.35%
0%
31.35%
2 Years
10.1%
0%
10.1%
3 Years
11.95%
0%
11.95%
4 Years
-10.16%
0%
-10.16%
5 Years
-9.24%
0%
-9.24%
BIOTON SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.87%
EBIT Growth (5y)
52.69%
EBIT to Interest (avg)
1.41
Debt to EBITDA (avg)
1.46
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.34
Tax Ratio
29.59%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.00%
ROE (avg)
1.05%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.62
EV to EBIT
108.94
EV to EBITDA
9.61
EV to Capital Employed
0.64
EV to Sales
1.49
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.59%
ROE (Latest)
-1.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
65.60
77.70
-15.57%
Operating Profit (PBDIT) excl Other Income
6.50
13.10
-50.38%
Interest
2.20
2.70
-18.52%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.80
-4.50
-28.89%
Operating Profit Margin (Excl OI)
-64.60%
47.30%
-11.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -15.57% vs 85.00% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -28.89% vs -32.35% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
207.80
181.60
14.43%
Operating Profit (PBDIT) excl Other Income
23.20
23.90
-2.93%
Interest
8.20
8.40
-2.38%
Exceptional Items
0.10
16.00
-99.38%
Consolidate Net Profit
-15.70
2.30
-782.61%
Operating Profit Margin (Excl OI)
-29.50%
-23.70%
-0.58%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.43% vs -22.13% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -782.61% vs 64.29% in Dec 2023
About BIOTON SA 
BIOTON SA
Pharmaceuticals & Biotechnology
Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
Company Coordinates 
Company Details
Ul. Staroscinska 5 , WARSZAWA None : 02-516
Registrar Details






